

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/616,769
Filed: 07/10/2003
1st Inventor: Y. MOMOSE
For: Neurotrophin Production Promotion Promoting Agent
Atty. Dkt. No. 2630 US1P



Art Unit: 1614
Examiner: tba
Allowed:
Batch:
Paper No.:

Supplemental Information Disclosure Statement

Commissioner for Patents
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached Form PTO-1449 previously submitted with a translation of the abstract. Applicants herewith provide English language translations of the entire documents identified in the previously submitted Information Disclosure Statement, as follows:

| <u>Reference Number</u> | <u>Document Author and Title</u> |
|-------------------------|---|
| A10 | Kawakita, T., et al. "Preparation of Benzoxazine Derivatives as Phospholipase A2 and Interleukin 1 Inhibitors" This reference will now be identified as JP 7242663 under "Foreign Patent Documents" |
| A11 | Gieldanowsky, Jerzy, et al. "Pharmacological Activity in the Group of New Substitute Thiazoloacetic and Thiazinocarboxyl Acid Derivatives" |
| A13 | Brown, Kevan, et al. "Nonsteroidal Antiinflammatory Agent. 1. 2,4-Diphenylthiazole-5-Acetic Acid and Related Compounds" |
| A16 | Sharma, Pawan K., et al. "Synthesis and Antiinflammatory Activity of Some 1,4-Dihydro-3-Methyl-1-(2-Thiazolyl)Pyrazolo 4,3-c(1,1)Benzothiazine 5,5-Dioxides" |
| A17 | Sawhney, S.N., et al. "Synthesis and Antiinflammatory Activity of Some 5-Thiazoleacetic Acids" |
| A19 | Jacobiec, Tadeusz, et al. "Studies on the Derivatives of 2-Amino-4-P-Chlorophenylthiazole-5-Acetic Acid" |
| A20 | Hirai, Kentaro, et al. "Synthesis of 2-Disubstituted-Amino-4-Arylthiazol-5-Ylalkanoic Acids" |

Legible copies of said listed references are herewith being provided to the Examiner.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfully submitted,




Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

Dated:

(847) 383-3372
(847) 383-3391

7/9/01

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

| Complete if Known | |
|------------------------|------------|
| Application Number | 10/616,769 |
| Filing Date | 07/10/2003 |
| First Named Inventor | Y. MOMOSE |
| Art Unit | 1614 |
| Examiner Name | tba |
| Attorney Docket Number | 2630 US1P |

U. S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

Examiner Signature _____ **Date Considered** _____

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

| <i>Complete if Known</i> | |
|--------------------------|------------|
| Application Number | 10/616,769 |
| Filing Date | 07/10/2003 |
| First Named Inventor | Y. MOMOSE |
| Art Unit | 1614 |
| Examiner Name | tba |
| Attorney Docket Number | 2630 US1P |

NON PATENT LITERATURE DOCUMENTS

| | | | |
|--------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | B2 | Gieldanowski,Jerzy, et al. "Pharmacological Activity in the Group of New Substituted Thiazoloacetic and Thiazinocarboxyl Acid Derivatives" Archivum Immunologiae et Thereapiae Experimentalis 26:921-929 (1978) | ✓ |
| | B3 | Brown, Kevan, et al. "Nonsteroidal Antiinflammatory Agents. 1. 2,4-Diphenylthiazole-5-acetic Acid and Related Compounds" Journal of Medicinal Chemistry 17(11): 1177-1181(1974) | ✓ |
| | B4 | Sharma, Pawan K., et al. "Synthesis and Antiinflammatory Activity of Some 1,4-Dihydro-3-methyl-1-(2-thiazoyl)pyrazolo[4,3-c][1,2]benzothiazine 5,5-Dioxides" Bull. Chem. Soc. Jpn. 66(12): 3843-3846 (1993) | ✓ |
| | B5 | Sawhney, S.N., et al. "Synthesis & Antiinflammatory Activity of Some 5-Thiazoleacetic Acids" Indian Journal of Chemistry 22B: 1044-1049(1983) | ✓ |
| | B6 | Jakobiec, Tadeusz, et al. "Studies on the Derivatives of 2-Amino-4-P-Chlorophenylthiazole-5-Acetic Acid" Archivum Immunologiae et Thereapiae Experimentalis, 27: 777-794 (1979) | ✓ |
| | B7 | Hirai, Kentaro, et al. "Synthesis of 2-Disubstituted-amino-4-arylhiazol-5-ylalkanoic Acids" Chem. Pharm. Bull. 25(9):2292-2299(1977) | ✓ |
| | | | |
| | | | |
| | | | |
| | | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.